The Increasing Access to Biosimilars Act of 2023 Introduced to CongressMarch 29th 2023
The Increasing Access to Biosimilars Act of 2023 (HR 1352), a bill that would direct HHS to establish a demonstration project within Medicare that would establish a shared savings model for biosimilars, was introduced to the House of Representatives.
A Long Time Coming: Dr Sophia Humphreys Details What’s Coming Down the Biosimilar PipelineMarch 23rd 2023
In the wake of adalimumab biosimilars hitting the US market, Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health, hyped up the current biosimilar market trends and the other products coming down the pipeline during her talk at the Festival of Biologics.
Published Data Coupled With Real-world Evidence Show Safety of Biosimilar-to-Biosimilar SwitchingMarch 22nd 2023
At the Festival of Biologics, Hillel Cohen, the executive director of scientific affairs at Sandoz, shared the current body of literature on biosimilar-to-biosimilar switching, saying that although there isn’t much published data, the vast real-world experience demonstrates the safety of this type of medication switch.
Uptake Barriers Will Deter Future Competitors From Investing in Biosimilars, Julie Reed WarnsMarch 21st 2023
At the Festival of Biologics, Juliana (Julie) Reed, executive director of the Biosimilars Forum, warned that without changes to encourage biosimilar uptake, companies will begin to ask the big question: Are biosimilars worth investing in?
How Community Oncologists Can Break Down Biosimilar Adoption BarriersMarch 19th 2023
On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.
CVS Predicts Interchangeability Won’t Drive Adalimumab Biosimilar AdoptionMarch 15th 2023
In a report from CVS Health, interchangeability will not be a primary factor in driving the adoption of adalimumab biosimilars referencing Humira, contradicting predictions from other sources that believe the designation will impact prescribing habits.
IQVIA's Michael Kleinrock Shares Why Smaller Manufacturers Are Investing in Biosimilar DevelopmentMarch 12th 2023
Better familiarity with biosimilars is enabling government agencies to reevaluate their approval requirements and encouraging smaller manufacturers to invest in biosimilar development, said Michael Kleinrock, lead research director for the IQVIA Institute for Human Data Science.
Eye on Pharma: FDA, EMA Accept Biosimilar Applications; Biosimilar Trials BeginMarch 9th 2023
The FDA and the European Medicines Agency (EMA) accepted applications for a trastuzumab biosimilar and an ustekinumab biosimilar, respectively, and Altos Biologics completed patient enrollment for a phase 3 trial assessing an aflibercept biosimilar.
White Paper Argues Increased Competition Will Improve Biosimilar Uptake, SavingsMarch 8th 2023
A white paper touting biosimilar successes in the United States reasoned that increased market competition will help improve utilization rates, generate substantial savings, and encourage payers to cover biosimilars.
Celltrion Publishes Data on Maintenance Therapy Using Infliximab BiobetterMarch 6th 2023
At the European Crohn’s and Colitis Organisation congress, Celltrion Healthcare shared positive safety and efficacy data on maintenance therapy including its infliximab biobetter allowing for subcutaneous administration, Remsima SC.
Biosimilars Gastroenterology Roundup for February 2023—Podcast EditionMarch 5th 2023
On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
Lilly Plans to Launch Insulin Biosimilar at 78% Discount to LantusMarch 2nd 2023
As Eli Lilly and Company announces that it will slash prices for its insulin products and cap out-of-pocket costs for insulin, the company shared that it will launch its interchangeable insulin biosimilar, Rezvoglar, at a 78% discount to the originator (Lantus).
Biosimilars Gastroenterology Roundup: February 2023March 1st 2023
As a new wave of biosimilars to treat inflammatory bowel disease— an umbrella term for Crohn disease and ulcerative colitis—enter the US market, a lot of clinical and policy news regarding adalimumab and infliximab biosimilars emerged throughout the month of February.
On the Come Up: What Vizient’s Report Says About Inflation and BiosimilarsFebruary 26th 2023
On this episode of Not So Different, Vizient’s Carina Dolan, PharmD, MS, BCOP, expounds on some of the results from Vizient’s recent edition of its Pharmacy Market Outlook Report, including how inflation could influence biosimilar utilization.
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab BiosimilarsFebruary 23rd 2023
In Cardinal Health’s 2023 Biosimilars Report, more than 60% of surveyed providers said they would only want to prescribe adalimumab biosimilars with interchangeability designations, suggesting the label may have a greater impact on uptake than originally expected.
Biosimilar Business Recap: New Ustekinumab Partnership; Similis Bio Biosimilar Programs; Celltrion Japan LaunchFebruary 23rd 2023
Fresenius Kabi announced a global partnership with Formycon for an ustekinumab biosimilar; Similis Bio partners with Novel351K to co-develop 3 biosimilars; and Celltrion Healthcare launched its bevacizumab biosimilar in Japan.
Access 2023: FDA’s Dr Jacqueline Corrigan-Curay Gives Updates on Biosimilar, Generic User Fee ProgramsFebruary 22nd 2023
Jacqueline Corrigan-Curay, MD, JD, principal deputy center director of the FDA's Center for Drug Evaluation and Research, gave a keynote presentation at Access 2023 on how the Biosimilar User Fee Act and the Generic Drug User Fee Act have developed over the last year.
IGBA Panelists Discuss the Global Reputation of Biosimilars, GenericsFebruary 21st 2023
Panelists at the annual meeting of the International Generic and Biosimilar Medicines Association (IGBA) offered insight into the current state of the global biosimilar and generic markets and why government agencies need to leverage these medicines to address challenges in the pharmaceutical space.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, BiopharmaFebruary 19th 2023
COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Access 2023: Panelists Weigh In on the Many Factors Influencing Biosimilar Uptake PatternsFebruary 16th 2023
Two presentations and a panel discussion at the annual meeting of the Association for Accessible Medicines (Access 2023) went over the current state of biosimilar uptake and the factors that help determine whether a biosimilar will experience good adoption rates.
Access 2023: Mark Cuban Teases Adding Biosimilars to Online Pharmacy, Champions GenericsFebruary 15th 2023
At the annual meeting of the Association for Accessible Medicines (Access 2023), Shark Tank’s Mark Cuban explained his dedication to and the inner workings of his online pharmacy that provides generic drugs to patients for significantly lower prices than traditional pharmacies.
FDA Issues CRL for Biocon Biologics, Viatris Avastin BiosimilarFebruary 14th 2023
Biocon Biologics and its partner Viatris received a complete response letter (CRL) for their biosimilar referencing Avastin (bevacizumab), the second CRL for the companies in 2023. The news comes as Biocon publishes increased revenues for biosimilars and generics.
What Will Be the Major Drivers Behind IQVIA's Predicted Biosimilars Uptake, Savings?February 14th 2023
Adalimumab and ustekinumab biosimilars aren't the only factors that will drive biosimilar adoption and savings through 2023, according to Michael Kleinrock, lead research director for the IQVIA Institute for Human Data Science.